Met Life Investment Management, LLC Arbutus Biopharma Corp Transaction History

Met Life Investment Management, LLC

$14.7 Billion
Q1 2024

A detailed history of Met Life Investment Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 61,872 shares of ABUS stock, worth $193,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,872

Holding current value

$193,040

% of portfolio

0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.26 - $2.92 $139,830 - $180,666	61,872 New	61,872 $159,000
Q2 2023 Apr 29, 2024	BUY	$2.24 - $3.06 $132,117 - $180,481	58,981 New	58,981 $135,000
Q1 2023 May 09, 2024	BUY	$2.23 - $3.1 $131,527 - $182,841	58,981 New	58,981 $179 Million
Q1 2023 May 15, 2023	BUY	$2.23 - $3.1 $33,106 - $46,022	14,846 Added 33.64%	58,981 $178,000
Q4 2022 May 10, 2024	SELL	$1.91 - $2.85 $27,353 - $40,814	-14,321 Reduced 24.5%	44,135 $102,000

Q4 2022 Jun 14, 2023	SELL	$1.91 - $2.85 $28,355 - $42,311	-14,846 Reduced 25.17%	44,135 $102,000
Q4 2022 Mar 22, 2023	SELL	$1.91 - $2.85 $27,353 - $40,814	-14,321 Reduced 24.5%	44,135 $102,000
Q4 2022 Feb 15, 2023	SELL	$1.91 - $2.85 $27,353 - $40,814	-14,321 Reduced 24.5%	44,135 $102,000
Q3 2022 May 10, 2024	BUY	$1.88 - $2.88 $43,826 - $67,138	23,312 Added 66.33%	58,456 $111,000
Q3 2022 Jun 14, 2023	SELL	$1.88 - $2.88 $987 - $1,512	-525 Reduced 0.89%	58,456 $111,000
Q3 2022 Mar 22, 2023	BUY	$1.88 - $2.88 $43,826 - $67,138	23,312 Added 66.33%	58,456 $111,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $43,826 - $67,138	23,312 Added 66.33%	58,456 $112,000
Q2 2022 May 10, 2024	SELL	$1.98 - $3.17 $8,878 - $14,214	-4,484 Reduced 11.32%	35,144 $95,000
Q2 2022 Jun 20, 2023	SELL	$1.98 - $3.17 $47,197 - $75,563	-23,837 Reduced 40.41%	35,144 $95,000
Q2 2022 Mar 22, 2023	SELL	$1.98 - $3.17 $8,878 - $14,214	-4,484 Reduced 11.32%	35,144 $95,000
Q2 2022 Aug 11, 2022	SELL	$1.98 - $3.17 $8,878 - $14,214	-4,484 Reduced 11.32%	35,144 $95,000
Q1 2022 May 10, 2024	BUY	$2.42 - $3.98 $95,899 - $157,719	39,628 New	39,628 $118,000
Q1 2022 Jun 20, 2023	SELL	$2.42 - $3.98 $46,834 - $77,024	-19,353 Reduced 32.81%	39,628 $118,000
Q1 2022 Mar 22, 2023	BUY	$2.42 - $3.98 $71,748 - $117,999	29,648 Added 297.07%	39,628 $118,000
Q1 2022 May 12, 2022	BUY	$2.42 - $3.98 $71,748 - $117,999	29,648 Added 297.07%	39,628 $118,000
Q4 2021 May 17, 2024	SELL	$3.11 - $4.61 $62,392 - $92,485	-20,062 Reduced 66.78%	9,980 $38,000
Q4 2021 Jun 21, 2023	SELL	$3.11 - $4.61 $152,393 - $225,894	-49,001 Reduced 83.08%	9,980 $38,000
Q4 2021 Mar 22, 2023	SELL	$3.11 - $4.61 $62,392 - $92,485	-20,062 Reduced 66.78%	9,980 $38,000
Q4 2021 Feb 15, 2022	SELL	$3.11 - $4.61 $62,392 - $92,485	-20,062 Reduced 66.78%	9,980 $39,000
Q3 2021 May 17, 2024	SELL	$2.65 - $4.62 $84,349 - $147,054	-31,830 Reduced 51.44%	30,042 $128,000
Q3 2021 Jun 21, 2023	SELL	$2.65 - $4.62 $76,688 - $133,698	-28,939 Reduced 49.06%	30,042 $128,000
Q3 2021 Mar 22, 2023	BUY	$2.65 - $4.62 $3,908 - $6,814	1,475 Added 5.16%	30,042 $128,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $79,611 - $138,794	30,042 New	30,042 $129,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $99,984 - $275,957	-28,567 Closed	0 $0
Q3 2018 Jul 13, 2023	SELL	$7.85 - $12.35 $317,163 - $498,977	-40,403 Reduced 68.5%	18,578 $175,000
Q3 2018 Mar 22, 2023	SELL	$7.85 - $12.35 $122,208 - $192,264	-15,568 Reduced 35.27%	28,567 $269,000
Q3 2018 Nov 14, 2018	BUY	$7.85 - $12.35 $224,250 - $352,802	28,567 New	28,567 $270,000

Others Institutions Holding ABUS

# of Institutions

130

Shares Held

82.2M

Call Options Held

4.82M

Put Options Held

546K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Arbutus Biopharma Corp Transaction History